The pairing works because the two peptides cut food intake through separate hormone systems that converge on one outcome, so their effects add rather than overlap. Semaglutide is an approved GLP-1 receptor agonist; cagrilintide is an investigational long-acting amylin analogue, and the co-formulation reported under the name CagriSema is not approved in the United States or the European Union, with a New Drug Application submitted to the FDA in December 2025 and a decision expected in 2026. The evidence sits at the human clinical level, the strongest of the three tiers, though every figure below is a trial average rather than an individual outcome.
| Feature | Semaglutide | Cagrilintide |
|---|---|---|
| Hormone class | GLP-1 receptor agonist, an incretin mimetic | Long-acting analogue of amylin |
| Main receptor territory | Arcuate nucleus, nucleus tractus solitarius, parabrachial nucleus | Calcitonin receptor complexes in the area postrema |
| Appetite effect reported | Lower hunger between meals, reduced pull of energy-dense food | Satiation, the signal that ends a meal |
| Half-life | About one week, via an albumin-binding fatty acid chain | About one week, via an albumin-binding fatty acid chain |
| Regulatory status | FDA-approved for chronic weight management | Investigational, not FDA-approved |
In a 68-week trial in adults with obesity and without diabetes, the co-formulated combination produced an average weight reduction of 20.4 percent of body weight under the primary analysis against 3.0 percent for placebo, and it remains investigational rather than approved.
Receptor binding is where most accounts stop and where the pharmacology actually starts. The GLP-1 receptor is a class B G-protein-coupled receptor, and the same intracellular cascade running in different cell types is what produces pancreatic, gastric, and appetite effects that look unrelated from the outside. That one-cascade-many-tissues pattern is also why the benefits and the side effects of this drug class cannot be pulled apart from each other.
The week-long duration of action comes from three engineered changes to native GLP-1: an aminoisobutyric acid substitution at position 8 that resists dipeptidyl peptidase-4, a second substitution at position 34, and a fatty diacid chain attached at lysine 26 through a linker that secures reversible albumin binding.
Amylin is not a minor hormone that happens to ride along with insulin; it is the signal that ends a meal. That single fact explains why an amylin analogue shows up as smaller meals rather than fewer eating occasions, and why native human amylin was never a workable drug: it aggregates into the same insoluble fibrils found in the pancreatic islets of many people with type 2 diabetes.
Cagrilintide is described as a non-selective agonist that activates calcitonin receptors alongside the AMY1, AMY2, and AMY3 amylin receptor subtypes, and the calcitonin-receptor contribution to reduced food intake rests on preclinical work rather than quantified human data.
The two agents do not share an entry point, they share a destination. Both deposit signal into the hindbrain cluster at the floor of the fourth ventricle, but they arrive through receptor populations that barely overlap, and that separation upstream is the structural reason neither one saturates the other.
Because cagrilintide acts mainly through area postrema calcitonin-receptor complexes and semaglutide through GLP-1 receptors spread across the nucleus tractus solitarius, parabrachial nucleus, and arcuate nucleus, partial blunting of one pathway does not silence the other.
The mechanistic story only earns attention if the effect size is real, and in the 68-week trial it was. What the numbers do not support is the word synergy: the arithmetic sits close to additive, which is exactly what two agents working on separate receptor systems that converge downstream would be expected to produce. The gap each one leaves is the other's territory, with semaglutide quieting background hunger and food reward while cagrilintide shortens the meal itself.
| Trial arm, 68 weeks, obesity without diabetes | Average weight reduction | Analysis |
|---|---|---|
| Cagrilintide plus semaglutide | 20.4 percent | Trial primary analysis |
| Cagrilintide plus semaglutide | 22.7 percent | Secondary, full-adherence estimate |
| Semaglutide alone | 14.9 percent | Trial primary analysis |
| Cagrilintide alone | 11.5 percent | Trial primary analysis |
| Placebo | 3.0 percent | Trial primary analysis |
Within the same 68-week trial the combination averaged 20.4 percent weight reduction against 14.9 percent for semaglutide alone and 11.5 percent for cagrilintide alone, a result closer to additive than synergistic, while the parallel trial in adults with type 2 diabetes averaged 13.7 percent.
Satiation and satiety get used interchangeably in ordinary speech, and the difference is the whole point here: satiation ends a meal, satiety suppresses eating between meals. Amylin signaling is primarily a satiation signal, GLP-1 signaling contributes to both, and slowed gastric emptying sits underneath as the physical mechanism that makes the same volume of food register as more.
The gastric-emptying delay from GLP-1 agonism attenuates through tachyphylaxis while the appetite effect persists, so slowed emptying accounts for the early treatment experience and the nausea profile rather than the long-term weight loss.
Glucose control improves by several routes at once, and the ones carrying the most clinical weight are not the ones that get the most attention. The low-hypoglycemia headline is accurate for this class used alone and misleading in combination therapy, since background insulin or a sulfonylurea can drive glucose too low as intake falls and insulin sensitivity improves.
Late-stage trials of the combination in people with type 2 diabetes reported A1c reductions on the order of 2 percentage points, with the size of the drop depending heavily on baseline A1c.
Marketing enthusiasm has run well ahead of the data on this question. Any substantial weight loss, whether from surgery, diet, or medication, removes fat-free mass along with fat, and the commonly cited lean fraction on incretin therapy of roughly a quarter to a third of total weight lost is broadly what caloric restriction produces at the same magnitude.
The human evidence available so far, limited to body-composition substudies rather than dedicated trials, does not establish a muscle-sparing advantage for the combination over a GLP-1 agonist alone.
One weekly injection is possible because both molecules use the same engineering trick: a fatty acid chain attached to the peptide backbone binds albumin reversibly, shielding the peptide from enzymatic degradation and from renal filtration while a small free fraction is released continuously to reach receptors. Matched half-lives are what make co-formulation workable, since neither agent ends up grossly over- or under-dosed on a shared schedule.
With a half-life near one week, each dose level takes roughly a month to reach steady state, which is why trial and clinical escalation schedules hold every step for several weeks and why an escalation that moves too fast cannot be corrected quickly.
This is the least settled thread in the amylin literature, and it stands on animal evidence rather than human evidence. Leptin is secreted in proportion to fat mass, yet people with obesity generally carry high circulating leptin alongside a blunted response to it, so administering more of it produces little weight loss, and the open question is whether amylin signaling reopens that channel.
Leptin resensitization remains a rodent-level hypothesis with no direct human evidence behind it in this combination, and amylin plus calcitonin receptor agonism accounts for the observed added effect without invoking it.
The gastrointestinal profile is not an incidental side effect, it is the shadow of the mechanism. The area postrema that both agents rely on for appetite suppression is also the chemoreceptor trigger zone, the region that starts nausea and vomiting in response to circulating substances, and delayed gastric emptying compounds what that activation begins.
Discontinuation for adverse events in the late-stage combination trials ran roughly 6 to 8 percent against roughly 3 to 4 percent on placebo, and the class contraindication in medullary thyroid carcinoma or multiple endocrine neoplasia type 2 continues to apply.
Educational use only. This article describes what the published scientific and clinical literature reports about CagriSema (cagrilintide and semaglutide). It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
